These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36944623)

  • 1. Effects of Vortioxetine on Cognition and Fatigue in Patients with Multiple Sclerosis and Depression: A Case Series Study.
    Gil-Sanchez A; Canudes M; Valcheva P; Nogueras L; González-Mingot C; Hervás JV; Peralta S; Solana M; Brieva L
    CNS Neurol Disord Drug Targets; 2024; 23(3):395-401. PubMed ID: 36944623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vortioxetine Treatment for Depression in Patients with Prodromal vs Mild Alzheimer's Disease: A Six-Month, Open-Label, Observational Study.
    Padovani A; Caratozzolo S; Benussi A; Galli A; Rozzini L; Cosseddu M; Turrone R; Pilotto A
    J Prev Alzheimers Dis; 2024; 11(2):375-381. PubMed ID: 38374744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
    Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ
    Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study.
    Mitsikostas DD; Doskas T; Gkatzonis S; Fakas N; Maltezou M; Papadopoulos D; Gourgioti R; Mitsias P
    Adv Ther; 2021 Mar; 38(3):1536-1551. PubMed ID: 33528792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalfampridine effects on cognition, fatigue, and dexterity.
    Korsen M; Kunz R; Schminke U; Runge U; Kohlmann T; Dressel A
    Brain Behav; 2017 Jan; 7(1):e00559. PubMed ID: 28127507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER.
    Triche EW; Ruiz JA; Olson KM; Lo AC
    Clin Neuropharmacol; 2016; 39(2):73-80. PubMed ID: 26818040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    Broicher SD; Filli L; Geisseler O; Germann N; Zörner B; Brugger P; Linnebank M
    J Neurol; 2018 May; 265(5):1016-1025. PubMed ID: 29464379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.
    Di Nicola M; Pepe M; Montanari S; Spera MC; Panaccione I; Simonetti A; Sani G
    Eur Neuropsychopharmacol; 2023 May; 70():21-28. PubMed ID: 36808043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between social cognition and fatigue, depressive symptoms, and anxiety in multiple sclerosis.
    Genova HM; Lancaster K; Lengenfelder J; Bober CP; DeLuca J; Chiaravalloti ND
    J Neuropsychol; 2020 Jun; 14(2):213-225. PubMed ID: 31152634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine
    Callegari C; Ielmini M; Caselli I; Lucca G; Isella C; Diurni M; Pettenon F; Poloni N
    Psychopharmacol Bull; 2019 Feb; 49(1):28-43. PubMed ID: 30858637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients.
    Biasi MM; Manni A; Pepe I; Abbatantuono C; Gasparre D; Iaffaldano P; Simone M; De Caro MF; Trojano M; Taurisano P; Paolicelli D
    BMC Psychol; 2023 Jul; 11(1):208. PubMed ID: 37452373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K; Pelicon K; Ledinek AH; Sega S
    Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
    Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
    Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial.
    Johnson SK; Diamond BJ; Rausch S; Kaufman M; Shiflett SC; Graves L
    Explore (NY); 2006 Jan; 2(1):19-24. PubMed ID: 16781604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
    J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
    [No Abstract]   [Full Text] [Related]  

  • 16. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
    Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
    Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters.
    Flachenecker P; Kümpfel T; Kallmann B; Gottschalk M; Grauer O; Rieckmann P; Trenkwalder C; Toyka KV
    Mult Scler; 2002 Dec; 8(6):523-6. PubMed ID: 12474995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open study with (-)-OSU6162 in multiple sclerosis-related fatigue.
    Haghighi S; Forsmark S; Carlsson A; Nilsson MKL; Carlsson ML; Schuit RC; Gottfries CG
    Acta Neurol Scand; 2018 Dec; 138(6):482-489. PubMed ID: 30132786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment.
    Romani A; Bergamaschi R; Candeloro E; Alfonsi E; Callieco R; Cosi V
    Mult Scler; 2004 Aug; 10(4):462-8. PubMed ID: 15327047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis.
    Badulescu S; Le GH; Wong S; Kwan ATH; Guo Z; Teopiz KM; Phan L; Subramaniapillai M; Rosenblat JD; Mansur RB; McIntyre RS
    Neurol Sci; 2024 Apr; 45(4):1335-1342. PubMed ID: 38321333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.